Aerie Pharmaceuticals
(NASDAQ) AERI
Aerie Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$213.94M
Net Income (TTM)
$36.55M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AERI News
Is Aerie Pharmaceuticals a Buy?
Is Aerie Pharmaceuticals a Buy?
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aerie Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
376
CEO
Rajkumar Kannan, MBA
Website
www.aeriepharma.comHeadquarters
Durham, NC 27703, US
AERI Financials
Key Financial Metrics (TTM)
Gross Margin
86%
Operating Margin
-23%
Net Income Margin
-39%
Return on Equity
-23%
Return on Capital
-15%
Return on Assets
-17%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$167.29M
Operating Income
$45.31M
EBITDA
$6.77M
Operating Cash Flow
$99.15M
Capital Expenditure
$3.29M
Free Cash Flow
$102.44M
Cash & ST Invst.
$139.80M
Total Debt
$260.64M
Aerie Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$36.13M
+23.3%
Gross Profit
$29.20M
+36.4%
Gross Margin
80.82%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
376
N/A
Net Income
$26.83M
+32.4%
EBITDA
$21.73M
+4.1%
Quarterly Fundamentals
Net Cash
$164.52M
-89.1%
Accounts Receivable
$73.88M
+14.4%
Inventory
$46.76M
+55.6%
Long Term Debt
$332.11M
+32.5%
Short Term Debt
$4.87M
+23.8%
Return on Assets
-17.34%
N/A
Return on Invested Capital
-14.79%
N/A
Free Cash Flow
$12.21M
+39.0%
Operating Cash Flow
$11.40M
+39.5%